Table 1 Basic characteristics of the studies included
Author | Year | Sample size | Gender (female) | Mean age (years) | Intervention and treatment frequency | Country | Study design | Follow-up | Outcome assessment | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
E | L | E | L | E | L | E | L | ||||||
Xu et al. [11] | 2020 | 30 | 25 | 83.33% | 84% | 47.2 ± 1.86 | 46.9 ± 1.76 | 1000 shocks, 1.5 bar, 6 Hz once a week, 3 consecutive weeks | Betamethasone 40 mg one treatment | China | RCT | Week 3, 9, 12 | VAS score, BQ score, sensory distal latency, motor distal latency, SNAP amplitude, CMAP amplitude |
Atthakomol et al. [12] | 2018 | 13 | 12 | 61.53% | 91.67% | 46 ± 9 | 53 ± 12 | 5000 shocks, 4 Bar 15 Hz one treatment | Triamcinolone acetonide 10 mg one treatment | Thailand | RCT | Week 1, 4, 12, 24 | VAS score, BQ score, symptom severity score, functional score, sensory distal latency, motor distal latency, SNAP amplitude, CMAP amplitude |
Sweilam et al .[13] | 2019 | 25 | 28 | 84% | 82.14% | 37.6 ± 8.5 | 36.8 ± 8.8 | 2500 shocks, 2 bars, 10 Hz two treatments, 1 week apart | Triamcinolone acetonide 40 mg one treatment | Egypt | RCT | Week 2, 4 | VAS score, BQ score, motor distal latency, CMAP amplitude, NCV of motor nerve |
Seok and Kim [14] | 2013 | 15 | 16 | 80% | 87.5% | 54.03 ± 19.47 | 49.67 ± 18.83 | 1000 shocks, 6 Hz one treatment | Triamcinolone acetonide 40 mg one treatment | Republic of Korea | RCT | Week 4, 12 | VAS score, LSQ symptom severity score, LSQ functional status score, NCV of sensory nerve, SNAP amplitude, CMAP amplitude, sensory distal latency, motor distal latency |
Tao et al. [15] | 2018 | 20 | 20 | 65% | 70% | 54.9 ± 5.7 | 54.7 ± 5.6 | Energy density 0.005–0.320 mJ/mm2, 0.5–20 Hz twice a week, 2 consecutive weeks | Compound betamethasone suspension 5 ml once a week, 2 consecutive weeks | China | RCT | Week 2 | VAS score, BQ score, quality of life assessment-short form 36, motor distal latency, CMAP amplitude, NCV of sensory nerve |